Filing Flows › Tango Therapeutics (TNGX) › Q1 2025
Tango Therapeutics (TNGX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Tango Therapeutics (TNGX) reported revenue of $5.4M for the first quarter 2025 (Q1 2025), -17% from a year earlier and +31% from the quarter before. Operating margin was -788.8%, net loss $39.9M (739.5% of revenue).
Tango Therapeutics, Q1 2025: revenue $5.4M (-17% year over year), operating margin -788.8%, net loss $39.9M, operating cash flow −$41.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.4M | +31% | -17% |
| Operating profit | −$42.5M | — | — |
| Net earnings | −$39.9M | — | — |
| Operating cash flow | −$41.7M | — | — |
What changed
Revenue was $5.4M in Q1 2025, down 17% year over year and up 31% from the previous quarter.
Operating costs exceeded revenue by $42.5M, an operating margin of -788.8%. Total costs fell 2% while revenue fell 17%. The quarter ended with a net loss of $39.9M, wider than the previous quarter's $37.7M loss.
Operating cash flow was −$41.7M. Non-cash charges added back $622K of depreciation and $7.3M of share-based compensation. Working capital and other items used $9.7M. Capital expenditures of $51K exceeded it, leaving free cash flow of −$41.7M.
Questions
What was Tango Therapeutics' revenue in the first quarter 2025?
Tango Therapeutics (TNGX) reported revenue of $5.4M for the first quarter 2025 (Q1 2025), -17% from a year earlier and +31% from the quarter before.
Was Tango Therapeutics profitable in the first quarter 2025?
Operating loss was $42.5M (-788.8% of revenue) and net loss $39.9M.
Source: Tango Therapeutics 10-Q on SEC EDGAR.